Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  BULGARIAN STOCK EXCHANGE  >  Sopharma AD    3JR   BG11SOSOBT18

SOPHARMA AD (3JR)
Mes dernières consult.
Most popular
Report
No quotes available
-- BGN   --.--%
2016 SOPHARMA AD : Notification
2016 SOPHARMA AD : Press release
2016 SOPHARMA AD : Press Release
 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Financials ( BGN)
Sales 2017 558 M
EBIT 2017 35,9 M
Net income 2017 -
Debt 2017 -
Yield 2017 2,38%
Sales 2018 579 M
EBIT 2018 37,9 M
Net income 2018 -
Debt 2018 -
Yield 2018 2,86%
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 0,99x
Capi. / Sales2018 0,96x
Capitalization 554 M
More Financials
Company
Sopharma AD engages in the provision of pharmaceutical business.Its operations include production and marketing of medical products, medicinal substances as well as dosage forms.It also involved in research, engineering, and implementation activities in the field of phytochemistry, chemistry, and... 
Sector
Pharmaceuticals
Calendar
11/03Investor Meeting
More about the company
Latest news on SOPHARMA AD
2016 SOPHARMA AD : Notification
2016 SOPHARMA AD : Press release
2016 SOPHARMA AD : Press Release
2016 SOPHARMA AD SOFIA : Press Relsease
2016 SOPHARMA AD SOFIA : Press release
2012 SOPHARMA AD SOFIA : Sopharma donates medicines for charity action
2012 SOPHARMA AD SOFIA : Fitness Center for the workers and employees of Sopharma AD
More news
Sector news : Generic Pharmaceuticals
06:27p JOHNSON & JOHNSON : California judge tosses $417 million talc cancer verdict aga..
10/20DJMERCK AND : to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
10/20 MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
10/20DJABBOTT LABORATORIES : Hacking Is a Risk for Pacemakers. So Is the Fix
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
More sector news : Generic Pharmaceuticals
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 5,07  BGN
Spread / Average Target 21%
Managers
NameTitle
Ognian Ivanov Donev Chairman, Chief Executive Officer & MD
Boris Anchev Borisov Chief Financial Officer
Iliyan Slavov Kolev Director-Technical Matters
S. Katzarova Head-Medical & Regulatory Affairs
Vessela Liubenova Stoeva Deputy Chairman
Sector and Competitors